BioStock: Coegin Pharma applies for clinical study application

There is a high demand for new innovative treatments against the precancerous skin condition actinic keratosis (AK). In the Nordics, Coegin Pharma is developing a drug targeting the cPLA₂α enzyme, which is involved in several inflammatory diseases, cancers and pre-cancerous conditions like AK. This week, the company submitted an application to the Danish Medicines Agency to begin a clinical trial with the drug candidate AVX001.

Read the full article at biostock.se:

https://www.biostock.se/en/coegin-pharma-applies-for-clinical-study-application/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/